Orion will be the exclusive partner for the distribution, marketing, and sales of Shilpa's Recombinant Human Albumin in Europe
This novel recombinant has been developed and is a patented novel recombinant Human Albumin 20% process
This marks an expansion of the companies' existing collaboration and further validates the use of Albumedix Recombumin rHA products in the manufacturing process and final formulation of critical vaccines
The product is synthetically developed as compared to the current process of drawing the same from blood plasma and is backed by a granted global patent
Subscribe To Our Newsletter & Stay Updated
